Formulations of AG10
Patent Information
- Application Number
- JP2024060790
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-08-17
- Filing Date
- 2024-04-04
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2039-08-16
AI Technical Summary
Existing pharmaceutical formulations of AG10, a small molecule inhibitor of protein-protein interactions, lack stability and consistency in pharmacokinetic data, making them unsuitable for oral administration.
Development of highly loaded tablet formulations of AG10 using high-grade microcrystalline cellulose and specific excipients, ensuring stability and consistent pharmacokinetic profiles.
The tablet formulations achieve high drug loading without erosion, maintaining dissolution rates and stability over time, providing consistent oral absorption.
Abstract
Description
[Background technology]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 765,154, filed August 17, 2018, the disclosure of which is incorporated herein by reference in its entirety.
[0002] STATEMENT REGARDING RIGHTS TO INVETIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT N / A
[0003] A reference to a "Sequence Listing," a table, or a computer program listing appendix submitted on a compact disc N / A
[0004] Aberrant protein interactions and aggregation, either due to protein misfolding or excessive activation of signaling pathways, are the underlying causes of numerous human degenerative diseases, therefore targeting protein-protein interactions (PPIs) is of therapeutic importance.
[0005] To date, the inhibitors of PPIs approved are proteins rather than small molecule inhibitors. For example, therapeutic monoclonal antibodies (mAbs) are used to treat cancer, autoimmune diseases, infectious diseases, and neurodegenerative diseases. Therapeutic mAbs are expensive to produce, require administration by injection, and may illicit an immune response in patients. For these reasons, the development of small molecule inhibitors of PPIs remains interesting.
[0006] One example of abnormal protein aggregation is the soluble protein transthyretin (TTR or prealbumin). Wild-type (WT) TTR is a 55 kDa homotetrameric protein present in blood and cerebrospinal fluid. Upon dissociation from the homotetrameric form, WT TTR dimers can misfold into amyloidogenic monomers. The formation of amyloidogenic monomers has been observed in WT TTR and over 100 different mutant variants. Studies have shown that stabilizing the tetrameric form of TTR inhibits the misfolding of amyloidogenic monomers and subsequent TTR amyloid formation.
[0007] Recent studies have identified 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid (AG10) as a promising candidate for treating TTR amyloid-related diseases, such as TTR amyloid cardiomyopathy and ATTR polyneuropathy. The compound is disclosed in WO 2014 / 100227. Despite the disclosure of this compound, improved pharmaceutical formulations that provide improved stability and consistent pharmacokinetic data remain elusive.
[0008] Thus, there is a need to produce pharmaceutical formulations suitable for administration to humans or other animals. The present disclosure addresses these needs and provides related advantages as well. Summary of the Invention
[0009] The present disclosure provides a high-loading tablet formulation of AG10 or a pharma- ceutically acceptable salt thereof and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants. In some embodiments, the tablet formulation is coated with a coating agent. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 shows a process flow diagram for preparing the AG10 formulation described in Example 2. [Diagram 2] FIG. 2 shows an image of the AG10 HCl coated tablets prepared in Example 2. [Diagram 3] FIG. 3 shows the dissolution profile of the AG10 solid tablet formulation described in Example 2. [Figure 4] FIG. 4 shows a process flow diagram for preparing the AG10 formulation described in Example 3. [Diagram 5] FIG. 5 shows the process flow for the preparation of the aqueous coating suspension or the AG10 formulation described in Example 3. [Figure 6] FIG. 6 shows images illustrating the absence of tablet edge erosion after friability testing of L018A (high hardness, left) and L018B (medium hardness, right) (at AG10 33.0%). [Figure 7] FIG. 7 shows images of edge erosion of large tablets after friability testing of L016 (left) and L017 (right) (both formulations with 40% AG10 formulation and maximum hardness). [Figure 8] FIG. 8 shows a process flow diagram for 33% AG10 HCl tablets as described in Example 4. [Figure 9] FIG. 9 shows a process flow diagram for 66.7% AG10 HCl tablets as described in Example 4. [Figure 10] Figure 10 shows the dissolution profile of 33.3% AG10 HCl tablets after storage under 40°C / 75%RH conditions: T=0 (open triangles); T=1 month (open diamonds); T=3 months (filled circles); T=6 months (filled squares). [Figure 11] Figure 11 shows the dissolution profile of 66.7% AG10 HCl tablets after storage under 40°C / 75%RH conditions: T=0 (open triangles); T=3 months (filled circles); T=6 months (filled squares). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Detailed Description of the Invention I. Overview The present disclosure is based in part on the discovery that formulations containing 40% or more AG10 can be successfully prepared as tablets. These tablets are particularly well suited for administration to both human and animal subjects, as these amounts meet the stability and pharmacokinetic requirements necessary for oral formulations. Other formulations, such as capsules, cannot meet these needs.
[0012] High loading immediate release AG10 tablets were successfully achieved using high grade microcrystalline cellulose. In contrast, tablet formulations above 33.3% AG10 using standard grade microcrystalline cellulose showed signs of tablet erosion after friability testing and reduced dissolution rates after extended storage.
[0013] II. Definition Unless otherwise specified, all technical and scientific terms used herein further include any method or material similar or equivalent to the method or material described herein that can be used in the practice of the present invention. They have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. For the purposes of the present invention, the following terms are defined.
[0014] As used herein, the terms "a," "an," or "the" include not only embodiments having one member, but also embodiments having a plurality of members. For example, the singular forms "a," "an," or "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells, and reference to "an agent" includes reference to one or more agents known to those of skill in the art.
[0015] As used herein, the term "about" refers to a range of values that includes a particular value, and that one of ordinary skill in the art would consider to be reasonably similar to the particular value. In some embodiments, the term "about" refers to within a standard deviation using measurements generally accepted in the art. In some embodiments, about refers to a range that covers + / - 10% of the particular value. In some embodiments, about refers to the particular value.
[0016] The term "tablet" refers to a solid pharmaceutical formulation, with or without a coating. The term "tablet" also refers to a tablet with one, two, three, or more layers, and each of the aforementioned types of tablets may or may not have one or more coatings. In some embodiments, the tablets of the present disclosure can be prepared by roller compaction or other suitable means known in the art. The term "tablet" also includes mini tablets, melt tablets, chewable tablets, effervescent tablets, and orally disintegrating tablets. The tablet comprises AG10 and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants. Optionally, to calculate the weight percentage of a tablet formulation that also includes a coating, the amount of the coating is not included in the calculation. That is, the weight percentages reported herein are for uncoated tablets.
[0017] The term "salt" refers to the acid salt or base salt of the compound of the present disclosure. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, etc.) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid, etc.) salts, quaternary ammonium (methyl iodide, ethyl iodide, etc.) salts. It is understood that pharmaceutically acceptable salts are non-toxic. Additional information regarding suitable pharmaceutically acceptable salts is described in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
[0018] III. EMBODIMENTS OF THE DISCLOSURE The present disclosure provides, inter alia, a tablet formulation of AG10 or a pharma- ceutically acceptable salt thereof. AG10 has the chemical formula:
[0019] [ka]
[0020] It is a compound having the formula:
[0021] In some embodiments, the pharma- ceutically acceptable salt of AG10 has the formula I
[0022] [ka]
[0023] where X is a pharma- ceutically acceptable anion of a protic acid.
[0024] A variety of protic acids are suitable for making pharma- ceutically acceptable salts of Formula I. It will be understood that the pharma- ceutically acceptable anion of the protic acid will depend on the protic acid used. For example, protic acids useful in the present disclosure include hydrochloric acid, hydrobromic acid, sulfonic acid, tosylic acid (p-toluenesulfonic acid), methanesulfonic acid, nitric acid, or acetic acid. Thus, the pharma- ceutically acceptable anion of the protic acid may be a chloride anion (Cl - ), bromide anion (Br - ), sulfonate anion (HS(O)O - ), tosylate anion (TsO - ), mesylate anion (MsO - ), nitrate anion (NO3 - ), and acetate anion (CHC(O)O - ), or a combination thereof.
[0025] In some embodiments, the pharma- ceutically acceptable anion of the protic acid is mesylate.
[0026] In some embodiments, the pharma- ceutically acceptable anion of the protic acid is tosylate.
[0027] In some embodiments, the pharma- ceutically acceptable anion of the protic acid is chloride, and the pharma- ceutically acceptable salt of Formula I has the formula (Ia):
[0028] [ka]
[0029] It is expressed as:
[0030] Pharmaceutically acceptable salts of formula I can be prepared using many conventional means in the art. For example, the free acid form of the compound of formula I may be contacted with a stoichiometric amount of a suitable acid in water, an organic solvent, or a mixture of the two. In some embodiments, the pharma- ceutically acceptable salts of formula I are prepared in a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile. In some embodiments, the pharma- ceutically acceptable salts of formula I are prepared by dissolving the compound of formula IX in water, adding an appropriate amount of HX to form a mixture, and adding a non-aqueous solvent such as the non-aqueous medium described above to crystallize the salt. In some embodiments, the appropriate amount of HX is a stoichiometric amount. It is understood that HX comprises hydrogen, and X is a pharma- ceutically acceptable anion of a protic acid as defined above.
[0031] The tablet formulation of the present disclosure may comprise, for example, about 40-85% by weight, or about 50-75% by weight, of AG10 or a pharma- ceutically acceptable salt thereof. In some embodiments, the tablet formulation comprises about 50-70% by weight of AG10 or a pharma- ceutically acceptable salt thereof. In some embodiments, the tablet formulation comprises about 50% by weight of AG10 or a pharma- ceutically acceptable salt thereof. In some embodiments, the tablet formulation comprises about 66.7% by weight of AG10 or a pharma- ceutically acceptable salt thereof. In some embodiments, the tablet formulation comprises about 75% by weight of AG10 or a pharma- ceutically acceptable salt thereof. In some embodiments, the tablet formulation comprises about 80% by weight of AG10 or a pharma- ceutically acceptable salt thereof. In some embodiments, the tablet formulation comprises about 85% by weight of AG10 or a pharma- ceutically acceptable salt thereof.
[0032] The amount of AG10 or a pharma- ceutically acceptable salt thereof in the tablet formulation may be about 0.1 to about 500 mg, about 0.1 to about 250 mg, or about 0.1 to about 100 mg. In some embodiments, the amount of AG10 present in the tablet formulation is about 10, 25, 50, 100, 200, 300, 400, or 500 mg. In some embodiments, the amount of AG10 present in the tablet formulation is about 50, 100, 200, or 400 mg. In some embodiments, the total weight of the tablet formulation (e.g., active ingredient and excipients--not including coating) is about 50 to about 1500 mg. For example, the total weight of the solid dosage form is about 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, or 1500 mg.
[0033] The tablet formulation of the present disclosure may include at least one component selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants, or other components. In some embodiments, the tablet formulation includes one or more excipients selected from high grade microcrystalline cellulose fillers, inorganic salt fillers, and lubricants.
[0034] In some embodiments, the tablet formulation of the present disclosure includes one or more fillers. Suitable fillers are as follows: In some embodiments, the one or more fillers are present in an amount of about 1-60, 5-55, 10-50, or 15-45% by weight. In some embodiments, the one or more fillers are present at about 42.5% by weight. In some embodiments, the one or more fillers are present at about 25.8% by weight. In some embodiments, the one or more fillers are present at about 17.5% by weight.
[0035] In some embodiments, the tablet formulation of the present disclosure includes one to three fillers. In some embodiments, the tablet formulation of the present disclosure includes one to two fillers. In some embodiments, the tablet formulation of the present disclosure includes two fillers.
[0036] Suitable fillers include, for example, oligosaccharides (e.g., lactose), sugars, starches, modified starches, sugar alcohols (e.g., mannitol, sorbitol, xylitol, lactitol), inorganic salts, cellulose derivatives (e.g., microcrystalline cellulose, silicified microcrystalline cellulose, cellulose, hypromellose), calcium sulfate, aluminum silicate, and magnesium silicate complexes, and oxides. Examples of inorganic salt fillers include phosphates, such as dibasic calcium phosphate dehydrate, sulfates, and silicon dioxide. In some embodiments, the one or more fillers include cellulose derivatives or alkaline earth metal salts, such as chlorides, phosphates, and sulfates. In some embodiments, the one or more fillers include cellulose derivatives and inorganic salts. In some embodiments, the one or more fillers are microcrystalline cellulose and silicon dioxide. In some embodiments, the one or more fillers are microcrystalline cellulose. In some embodiments, the microcrystalline cellulose is a high grade microcrystalline cellulose.
[0037] High grade microcrystalline cellulose is a cellulose-derived product that has unique properties that are not a primary feature of more standard preparations of microcrystalline cellulose. For example, in some embodiments, high grade microcrystalline cellulose is characterized by cellulose polymers with a spherical morphology and porous structure. These properties are found in CEOLUS™ UF grade microcrystalline cellulose (e.g., UF-702 and UF-711) and similar available products. In some embodiments, high grade microcrystalline cellulose is characterized by cellulose polymers with a needle-like particle shape. These properties are found in CEOLUS™ KG grade microcrystalline cellulose (e.g., KG-802, KG-1000, etc.).
[0038] The high grade cellulose filler may be present in an amount of about 1-60% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 5-55% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 10-50% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 15-45% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 45% by weight. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 17%. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 26%. In some embodiments, the high grade microcrystalline cellulose is present in an amount of about 42%.
[0039] In some embodiments, the tablet formulation of the present disclosure includes one or more binders. Suitable binders are as follows: In some embodiments, the one or more binders are present in an amount of about 0.5-15, about 0.5-10, or about 1-10% by weight. In some embodiments, the one or more binders are present in an amount of about 3-8% by weight. In some embodiments, the one or more binders are present in an amount of about 5% by weight.
[0040] In some embodiments, the tablet formulation of the present disclosure comprises one to three binders. In some embodiments, the tablet formulation of the present disclosure comprises one binder.
[0041] Suitable binders include, for example, povidone, lactose, starch, modified starch, sugars, gum arabic, gum tragacanth, guar gum, pectin, wax binders, methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, copolyvidone, gelatin, sodium alginate, and the like. Non-cellulosic binders include polymers and other binders that lack a cellulose backbone. Examples of non-cellulosic binders include povidone, lactose, starch, modified starch, gums, guar gum, pectin, waxes, gelatin, alginates, and the like. In some embodiments, the formulation includes a non-cellulosic binder, such as povidone or copovidone. In some embodiments, the non-cellulosic binder is copovidone.
[0042] In some embodiments, the tablet formulation of the present disclosure includes one or more disintegrants. Suitable disintegrants are as follows: In some embodiments, the one or more disintegrants are present in an amount of about 1-15, about 1-12, or about 1-10% by weight. In some embodiments, the one or more disintegrants are present in an amount of about 3-8% by weight. In some embodiments, the formulation includes about 3, 4, 5, 6, 7, or 8% by weight of disintegrant. In some embodiments, the formulation includes about 6% by weight of disintegrant.
[0043] In some embodiments, the tablet formulation of the present disclosure comprises one to three disintegrants. In some embodiments, the tablet formulation of the present disclosure comprises one disintegrant.
[0044] Suitable disintegrants include, for example, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, sodium starch glycolate, cornstarch. In some embodiments, the formulation includes a disintegrant, such as sodium starch glycolate, or crospovidone. In some embodiments, the disintegrant is croscarmellose sodium.
[0045] In some embodiments, the tablet formulation of the present disclosure includes one or more lubricants. Suitable lubricants are as follows: In some embodiments, the one or more lubricants are present in an amount of about 0.1-8, 0.5-5, 0.5-3% by weight. In some embodiments, the one or more lubricants are present in an amount of about 0.5, 0.75, 1, 1.5, 2, 3, 4, or 5% by weight. In some embodiments, the one or more lubricants are present in an amount of about 2% by weight. In some embodiments, the one or more lubricants are present in an amount of about 1.5% by weight.
[0046] In some embodiments, the tablet formulation of the present disclosure comprises one to three lubricants. In some embodiments, the tablet formulation of the present disclosure comprises one lubricant.
[0047] Suitable lubricants include, for example, magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax, hydrogenated vegetable oils, mineral oils, polyethylene glycol, and sodium stearyl fumarate. In some embodiments, the one or more lubricants are magnesium stearate and / or sodium stearyl fumarate. In some embodiments, the one or more lubricants are magnesium stearate.
[0048] Other suitable fillers, disintegrants, lubricants, and other excipients that can be used are described in Handbook of Pharmaceutical Excipients, 2nd Edition, American Lachman, Leon, 1976; Pharmaceutical Dosage Forms: Tablets Volume 1, 2nd Edition, Lieberman, Herbert A., et al, 1989; Modern Pharmaceutics, Banker, Gilbert and Rhodes, Christopher T, 1979; and Remington's Pharmaceutical Sciences, 15th Edition, 1975, each of which is incorporated herein by reference in its entirety.
[0049] In some embodiments, the tablet is coated with a coating agent. Suitable coating agents include ethylcellulose, polymethacrylate, and coating products sold by OPADRY™. In some embodiments, the coating agent is Opadry Clear, Opadry Blue 13B50579, Opadry White 33628707, Opadry QX 321A180025, or Opadry II (33G28707). In some embodiments, the coating agent is Opadry White 33628707. In some embodiments, the coating agent is Opadry QX 321A180025. In some embodiments, the coating agent is Opadry II (33G28707). To calculate the weight percentage of the tablet formulation, the amount of the coating agent is not included in the calculation. That is, the weight percentages reported herein are for uncoated tablets.
[0050] In some embodiments, the tablet formulation comprises about 40-85% by weight of AG10 or a pharma- ceutical acceptable salt thereof; about 5-55% by weight of one or more fillers; about 0-15% by weight of one or more binders; about 1-15% by weight of one or more disintegrants; and about 0.1-8% by weight of one or more lubricants. In some embodiments, the described formulations include a coating agent.
[0051] In some embodiments, the tablet formulation comprises about 50% by weight of AG10 or a pharma- ceutical acceptable salt thereof; about 42.5% by weight of one or more fillers; about 6% by weight of a disintegrant; and about 1.5% by weight of a lubricant. In some embodiments, the formulation described comprises a coating agent.
[0052] In some embodiments, the tablet formulation comprises about 66.7% by weight of AG10 or a pharma- ceutical acceptable salt thereof; about 25.8% by weight of one or more fillers; about 6% by weight of a disintegrant; and about 1.5% by weight of a lubricant. In some embodiments, the formulation described comprises a coating agent.
[0053] In some embodiments, the tablet formulation of the present disclosure is at least 75% dissolved after 10 minutes in 0.1 N HCl solution at 37±0.5° C. in Apparatus II (paddle) with a paddle speed of about 50 rpm. In some embodiments, the tablet formulation of the present disclosure is at least 85% dissolved after 10 minutes in 0.1 N HCl solution at 37±0.5° C. in Apparatus II (paddle) with a paddle speed of about 50 rpm. In some embodiments, the tablet formulation of the present disclosure is at least 95% dissolved after 10 minutes in 0.1 N HCl solution at 37±0.5° C. in Apparatus II (paddle) with a paddle speed of about 50 rpm. In some embodiments, the tablets tested were prepared within one week of the dissolution test. In some embodiments, the tablets tested were prepared at least one month before the dissolution test was performed. In some embodiments, the tablets tested were prepared at least three months before the dissolution test was performed. In some embodiments, the tablets to be tested were prepared at least 6 months before conducting the dissolution test. In some embodiments, the tablets were incubated at 25° C. at 60% relative humidity (RH) for 1 month before conducting the dissolution test. In some embodiments, the tablets were incubated at 25° C. at 60% relative humidity (RH) for 2 months before conducting the dissolution test. In some embodiments, the tablets were incubated at 25° C. at 60% relative humidity (RH) for 3 months before conducting the dissolution test. In some embodiments, the tablets were incubated at 40° C. at 75% relative humidity (RH) for 1 month before conducting the dissolution test. In some embodiments, the tablets were incubated at 40° C. at 75% relative humidity (RH) for 3 months before conducting the dissolution test. In some embodiments, the tablets were incubated at 40° C. at 75% relative humidity (RH) for 6 months before conducting the dissolution test. EXAMPLES
[0054] IV. Working Examples The following examples are offered to illustrate, but not to limit, the claimed invention.
[0055] Example 1: Evaluation of capsules and tablets; capsules provide inconsistent oral pharmacokinetic data The pharmacokinetics of AG10 was determined when administered once daily by oral gavage to dogs for 3 days at 20, 60, and 200 mg / kg (Study No. 1). Each group consisted of 2 animals / sex / group. Blood samples were collected from each animal on day 1 pre-dose, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours post-dose, on day 3 pre-dose, and 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose. Plasma samples were analyzed for AG10 by LC-MS / MS. Overall, the mean C max and AUC 0-24 No sex differences were observed in the values. Therefore, the results for the 20 mg / kg group are shown in Table 1 below as the combined values by sex.
[0056] The pharmacokinetics of AG10 was also measured after oral administration to non-naive male and female beagle dogs (Study No. 2). The study design included three treatment groups (n=2 / sex / group). Groups 1 and 2 received 5 mg / kg and 20 mg / kg AG10 in a 0.5% methylcellulose (MC) formulation, respectively. Group 3 animals received 20 mg / kg AG10 in the form of a gelatin capsule. Blood samples were collected pre-dose and approximately 2, 4, 6, 8, 12, and 24 hours post-dose. Plasma samples were analyzed for AG10 by LC-MS / MS. Plasma exposure (AUC) of AG10 in dogs administered 20 mg / kg AG10 as a suspension in 0.5% methylcellulose was 0.01 mg / kg. 0-24 ) were similar to those obtained in Study No. 1 (Table 1). Plasma exposure of AG10 was also similar in dogs administered the same doses either as a suspension in 0.5% methylcellulose or as excipient-free gelatin capsules.
[0057] AG10 was orally administered to four male beagle dogs as 50 mg tablets, 200 mg tablets, and 200 mg capsules (No. 3). Blood samples were collected pre-dose and approximately 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 96 hours post-dose. Plasma samples were analyzed for AG10 by LC-MS / MS. C in dogs administered 200 mg tablets and 200 mg capsules was max and AUC 0-inf The values of were not significantly different (P<0.05) as determined by unpaired t-test (C max and AUC 0-inf P values of 0.0788 and 0.0995).
[0058] [Table 1]
[0059] In dog studies comparing methylcellulose formulations of AG10, the time to maximum concentration (Tmax) was 0.44 ± 0.38 hours in Study No. 1 and 2.5 ± 1 hours in Study No. 2. The capsules in Study No. 2 were formulated without excipients and showed less variability (Tmax = 2 ± 0 hours) than the methylcellulose control. In Study No. 3, the maximum exposure of the AG10 tablets was comparable to that of the capsules, but the inter-animal variability in absorption of AG10 was greater in the four animals orally administered capsules containing excipients. For the 50 mg tablets, the time to maximum concentration (Tmax) was 0.500 ± 0 hours, and for the 200 mg tablets, the Tmax was 1.00 ± 0 hours. For the 200 mg capsules containing excipients, the Tmax was more variable at 1.38 ± 0.750 hours. Thus, in a direct comparison, the tablets provided more consistent oral absorption of AG10.
[0060] Example 2: High Load Immediate Release AG10 Tablet Formulation The following example illustrates the successful preparation of a tablet formulation high in AG10.
[0061] Tablet formulations containing different amounts of AG10 were prepared. Table 2 provides information regarding the relative amounts of the ingredients used in each formulation.
[0062] [Table 2]
[0063] After compression, the tablets were tablet coated with Opadry QX white.
[0064] Tablets were prepared using the general diagram provided in Figure 1. Table 3 below provides exemplary amounts used in formulating a tablet formulation containing 66.7% AG10 HCl (Batch 2), and Tables 4 and 5 provide a listing of the equipment used and an overview of the steps taken to prepare the tablet formulation. A similar process was followed in preparing Batch 1 and Batch 3 referenced in Table 2.
[0065] [Table 3]
[0066] [Table 4]
[0067] [Table 5-1] [Table 5-2]
[0068] Photographs of 50% (w / w) and 66.7 (w / w) AG10 HCl coated tablets are shown in Figure 2. The 50% tablets were compressed with 8 x 17.5 mm capsule-shaped tooling and the 66.7% tablets were compressed with 7.5 x 15 mm capsule-shaped tooling. The physical properties of the two tablets shown are summarized in Table 6.
[0069] [Table 6]
[0070] Measurement of wear and tear: Tablet friability was measured according to the United States Pharmacopoeia method, as reported in Table 6. <1216> The tablet was evaluated based on the weight loss percentage of NLT 6.5 g disintegrated in a friability tester (model EF-2, Electrolab) for 100 rounds at 25 rpm according to the Friability Tester (FFT) 2010. The tablets were de-dusted and the weight loss caused by crushing or abrasion was recorded as the weight loss percentage. A friability of less than 1% is considered acceptable.
[0071] Next, the dissolution profiles of 50% (w / w) and 66.7 (w / w) AG10 HCl coated tablets were determined. Dissolution experiments were performed by placing the tablet formulations in 0.1 N HCl solutions as described in Table 7.
[0072] [Table 7]
[0073] Figure 3 shows the dissolution profiles of 50% (w / w) and 66.7 (w / w) AG10 HCl coated tablets. The dissolution experiments were performed without significant incubation time after the tablets were formulated. As can be seen in Figure 3, dissolution was 100% released within 10 minutes for both tablets.
[0074] Example 3: AG10 More than 33.3% of tablet formulations exhibited tablet erosion during friability testing The following example describes a tablet formulation of AG10 that was unable to exceed a drug load of 33.3% without undergoing tablet erosion during friability testing.
[0075] A formulation of AG10 was prepared as generally outlined in Figure 4 and Figure 5. The amounts of AG10 and other components are the areas listed in Table 8.
[0076] [Table 8]
[0077] Each of the above formulations was prepared as 200 mg tablets and subjected to friability testing as described in Example 2. Tablets L018A and L018B prepared at 33.0% drug loading (and compressed at high and medium hardness kP values, respectively) were resistant to disintegration and showed only minor, if any, tablet edge erosion after friability testing. See Figure 6. In comparison, L016 and L017 prepared at 40% drug loading and compressed at maximum attainable hardness showed significant tablet edge erosion after friability testing. See Figure 7.
[0078] The above formulation used a standard grade of microcrystalline cellulose, and the resulting tablets containing more than 33.0% AG10 had friability issues that precluded clinical use. In comparison, the formulation of Example 2 used a high grade of microcrystalline cellulose, which provided tablets with favorable physical properties and were reliably less prone to disintegration.
[0079] Example 4: "Accelerated Stability Conditions" Dissolution Study Demonstrates Stability of High Load AG10 Tablet Formulation The following examples describe the preparation of an immediate release tablet formulation containing 33% AG10 HCl (200 mg) with standard microcrystalline cellulose and a tablet formulation containing 66.7% AG10 HCl (400 mg) with a high grade microcrystalline cellulose, and subsequent dissolution testing.
[0080] The formulation of each tablet is shown in Tables 9 and 10.
[0081] [Table 9] a. The actual amount of AG10 hydrochloride was adjusted based on the strength of the drug substance, equivalent to 177.82 mg of AG10 free base. The actual amount of silicified microcrystalline cellulose was based on a concomitant reduction such that the target core weight remained at 606 mg. b. Prosolv HD 90 d. Solutab type A e. Plasdone S-630 f. Ligamed MF-2-V g. Purified water is used in the film coating process and is removed during the process h. Represents a weight gain of 3% of the tablet core weight. Opadry White, Colorcon 33G28707, contains hypromellose (European Pharmacopoeia), titanium dioxide (European Pharmacopoeia), and triacetin (European Pharmacopoeia).
[0082] [Table 10] a. The actual amount of AG10 hydrochloride was adjusted based on the strength of the drug substance and is equivalent to 355.64 mg of AG10 free base. The actual amount of microcrystalline cellulose was based on a concomitant reduction such that the target core weight remained at 600 mg. b. Ceolus UF-711 or equivalent c. Ac-Di-Sol SD711 or equivalent d. Syloid 244 FP or equivalent e. Hyqual 5712, Ligamed MF-2-K, or equivalent f. Purified water is used in the film coating process and is removed during the process g.Represents a weight gain of 4% of the tablet core weight. Opadry QX White, Colorcon 321A180025 contains GMCC type 1 / mono- and diglycerides, polyethylene glycol polyvinyl alcohol graft copolymer, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.
[0083] The manufacturing processes for the two tablet formulations are shown in Figures 8 and 9.
[0084] 33% AG10 HCl tablets were bottled and placed under accelerated storage conditions (40° C. / 75% relative humidity (RH)). Figure 10 shows that storage under accelerated storage conditions significantly decreased the dissolution rate of 33% AG10 HCl tablets.
[0085] The 66.7% AG10 HCl tablets were bottled and placed under accelerated storage conditions. Figure 11 shows that the 400 mg AG10 HCl tablets showed no decrease in dissolution rate after 6 months of storage.
[0086] Both formulations of AG10 HCl tablets were evaluated using the same dissolution method (USP 2 apparatus (paddle), 900 mL 0.1 N HCl, 75 RPM, 37° C.) for release and stability studies. The 66.7% AG10 HCl tablet formulation was superior to the 33% AG10 HCl tablet formulation in terms of dissolution rate after storage, indicating that the 66.7% AG10 HCl tablets have improved storage capabilities.
[0087] Although the foregoing invention has been described in some detail by way of illustration and example for clarity of understanding, those skilled in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims.Furthermore, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.In the event of a conflict between this application and a reference provided herein, this application shall control.
Claims
1. a. about 400 mg of 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid hydrochloride; and From about 1% to about 60% by weight of a high grade microcrystalline cellulose that is UF-702, UF-711, KG-802, KG-1000, or a combination thereof. A tablet comprising: b. Optionally, a coating agent and the total weight of the tablet is from about 470 mg to about 1000 mg.
2. 10. The pharmaceutical formulation of claim 1, wherein the tablet comprises from about 5% to about 55% by weight of high grade microcrystalline cellulose.
3. 10. The pharmaceutical formulation of claim 1, wherein the tablet comprises from about 10% to about 50% by weight of high grade microcrystalline cellulose.
4. 10. The pharmaceutical formulation of claim 1, wherein the tablet comprises from about 15% to about 45% by weight of high grade microcrystalline cellulose.
5. 10. The pharmaceutical formulation of claim 1, wherein the tablet comprises about 26% by weight of high grade microcrystalline cellulose.
6. The pharmaceutical formulation of any one of claims 1 to 5, wherein the tablet has a total weight of about 533 mg to about 800 mg.
7. The pharmaceutical formulation according to any one of claims 1 to 5, wherein the total weight of the tablet is about 600 mg.
8. The tablet comprises: Approximately 400 mg of 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid hydrochloride; Approximately 153.5 mg high grade microcrystalline cellulose; Approximately 36 mg of croscarmellose sodium About 1.5 mg of silicon dioxide; and Approximately 9 mg of magnesium stearate 8. The pharmaceutical formulation of claim 7, comprising:
9. 9. The pharmaceutical formulation according to any one of claims 1 to 8, wherein the pharmaceutical formulation is at least 75% dissolved after dissolution testing in 0.1 N HCl solution at 37±0.5° C. for 10 minutes in Apparatus II (Paddle) with a paddle speed of about 50 rpm.
10. 10. The pharmaceutical formulation of claim 9, wherein the dissolution test is performed at least three months after preparation of the pharmaceutical formulation.
11. 10. The pharmaceutical formulation of claim 9, wherein the dissolution test is performed at least six months after preparation of the pharmaceutical formulation.
12. 9. The pharmaceutical formulation according to any one of claims 1 to 8, wherein the pharmaceutical formulation is at least 75% dissolved after dissolution testing in 900 mL of 0.1 N HCl solution at 37±0.5° C. for 10 minutes in Apparatus II (Paddle) with a paddle speed of about 75 rpm.
13. 13. The pharmaceutical formulation of claim 12, wherein the dissolution test is performed at least three months after preparation of the pharmaceutical formulation.
14. 13. The pharmaceutical formulation of claim 12, wherein the dissolution test is performed at least six months after preparation of the pharmaceutical formulation.
15. The pharmaceutical formulation of any one of claims 1 to 14, wherein the coating agent is present in an amount of about 4% by weight of the tablet.
